Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters

Alison M. McDonnell1,2†, Alistair Cook1,2†, Bruce W. S. Robinson1,2,4, Richard A. Lake1,2† and Anna K. Nowak1,2,3†

Abstract

Background: CD40 signalling can synergise with chemotherapy in preclinical cancer models, and early clinical studies are promising. We set out to define the immunological changes associated with this therapeutic combination to identify biomarkers for a response to the therapy. Here, we present serial immunomonitoring examining dendritic cell and T cell subpopulations over sequential courses of chemoimmunotherapy.

Methods: Fifteen patients with mesothelioma received up to six 21-day cycles of pemetrexed plus cisplatin chemotherapy and anti-CD40 (CP-870,893). Peripheral blood was collected weekly, and analysed by flow cytometry. Longitudinal immunophenotyping data was analysed by linear mixed modelling, allowing for variation between patients. Exploratory analyses testing for any correlation between overall survival and immunophenotyping data were undertaken up to the third cycle of treatment.

Results: Large statistically significant cyclical variations in the proportions of BDCA-1+, BDCA-2+ and BDCA-3+ dendritic cells were observed, although all subsets returned to baseline levels after each cycle and no significant changes were observed between start and end of treatment. Expression levels of CD40 and HLA-DR on dendritic cells were also cyclically modulated, again without significant change between start and end of treatment. CD8 and CD4 T cell populations, along with regulatory T cells, effector T cells, and markers of proliferation and activation, showed similar patterns of statistically significant cyclical modulation in response to therapy without changes between start and end of treatment. Exploratory analysis of endpoints revealed that patients with a higher than average proportion of BDCA-2+ dendritic cells (p = 0.010) or a higher than average proportion of activated (ICOS+) CD8 T cells (0.022) in pretreatment blood samples had better overall survival. A higher than average proportion of BDCA-3+ dendritic cells was associated with poorer overall survival at both the second (p = 0.008) and third (p = 0.014) dose of anti-CD40.

(Continued on next page)
Conclusions: Substantial cyclical variations in DC and T cell populations during sequential cycles of chemoimmunotherapy highlight the critical importance of timing of immunological biomarker assessments in interpretation of results and the value of linear mixed modelling in interpretation of longitudinal change over a full treatment course.

Trial registration: Australia New Zealand Clinical Trials Registry number ACTRN12609000294257 (18th May 2009).

Keywords: Mesothelioma, Dendritic cells, Prognosis

Background

As a variety of immunotherapies progress toward clinical approval, it is becoming more important to identify biomarkers to assess the clinical activity of these drugs; both to begin to understand what immunobiological changes are induced, and to identify those patients who are likely to benefit from these potentially toxic and often costly treatments. The addition of chemotherapy to immunotherapy in combination treatments is under intense investigation, however there is limited understanding of how concurrent chemotherapy may affect putative biomarkers of immunotherapy, and how to analyse and interpret these in the context of the cyclical changes in immunological parameters induced by cytotoxic treatments. Here, we present further immune biomarker data from a recent chemoimmunotherapy clinical trial conducted in patients with mesothelioma, and discuss the complexity of interpreting this information in the context of prediction and prognosis.

CD40 is a member of the TNF receptor superfamily primarily expressed on antigen-presenting cells (APC), e.g. dendritic cells (DC), B cells and monocytes, but also found on some non-lymphoid cells such as epithelial and endothelial cells, fibroblasts, and some tumours [1]. During the T cell-mediated immune response, CD40 ligand (CD40L; CD154) -expressing CD4 helper T cells can activate APC through CD40 signalling. These APC can in turn provide a ‘licence-to-kill’ signal to CD8 cytotoxic T cells - the main effectors in immune-mediated tumour regression [2].

Extensive preclinical studies of anti-CD40 therapy have shown efficacy in various tumour model systems, and several clinical agents targeting the CD40 signalling axis have been or are currently under investigation [3]. CP-870,893 is a fully human IgG CD40 agonist antibody that has shown promise as a single agent in patients with solid tumours, although overall response rates are still low [4]. Although CP-870,893 infusion was predicted from preclinical studies to induce tumour-specific cell-mediated immune responses, this remains to be fully confirmed in the clinical setting.

Agonistic anti-CD40 can synergise with chemotherapy and cure advanced tumours in mice, especially when administered after chemotherapy [5, 6]. This post-chemotherapy activity of agonistic anti-CD40 is hypothesised to occur by activating DC that have become ‘loaded’ with antigen from chemotherapy-induced tumour cell death, inducing expression of costimulatory molecules CD80 and CD86 and increased production of IL12 amongst other cytokines [7]. CP-870,893 has been investigated in conjunction with chemotherapy in early phase clinical trials, mostly in patients with advanced, treatment-resistant disease [7, 8]. In studies in pretreated patients, around 20% of participants achieved objective tumour regression. In our recent first-line mesothelioma trial (a phase Ib dose escalation study in combination with chemotherapy), 40% of patients achieved a partial response [9].

Currently identified pharmacodynamic effects of CP-870,893 as a monotherapy are most obvious in the B cell compartment, with depletion and activation of peripheral B-cells occurring within 72 h of infusion [4]. Previous studies have also reported detectable modulation of DC by CP-870,893; in particular, depletion of CD11c +CD123dimCD14 - expressing DC and increased HLA-DR expression by monocyte-derived DC [10, 11]. Weekly CP-870,893 monotherapy halved circulating lymphocyte concentrations after 48 h before returning to pre-treatment levels; this depletion was not observed when dosing occurred every three weeks [4, 10]. Thus, the pharmacodynamic effects of CP-870,893 are still somewhat undefined – particularly when combined with chemotherapy. Specifically, prolonged immune modulation over the longer term of a full course of treatment has not been characterised.

We recently showed that B-cell depletion and activation also occurs over several cycles of combined CP-870,893 plus pemetrexed and cisplatin chemotherapy in patients with mesothelioma [9]. Here, we present further in-depth flow cytometric analysis of patient peripheral blood mononuclear cells (PBMC) collected longitudinally throughout this study, in order to enhance our understanding of the immunobiology of combination chemoimmunotherapy and the unique challenges and considerations of analysis in this setting. We identify cyclical variations in PBMC subpopulations repeated with each cycle of chemo-immunotherapy, and identify potential relevant biomarkers of clinical activity in
dendritic cells, CD8+ effector cells and regulatory T cells in response to anti-CD40 agonist treatment in the context of chemotherapy. We present statistical analysis techniques which may inform other investigators in serial immunomonitoring of chemoimmunotherapy.

**Methods**

**Patients**

**Clinical trial designs**

The clinical trial was a prospective, single-centre, phase Ib trial of cisplatin and pemetrexed with CP-870,893 [9]. A 3 + 3 phase I design was used with a 6-patient expansion cohort at the maximum tolerated dose (MTD) of CP-870,893. The primary endpoint was the MTD of CP-870,893. Secondary endpoints included toxicity (NCI CTC Version 3.0), objective tumour response as measured by the modified RECIST criteria [12] and by fluorodeoxyglucose positron emission tomography (FDG-PET) [13], time to progression (TTP), and overall survival (OS).

**Eligibility**

Eligibility criteria have been previously described in detail [9]. In brief, all patients had confirmed malignant pleural mesothelioma, Eastern Co-operative Oncology Group (ECOG) performance status (PS) 0–1, and were planned for first-line cisplatin/pemetrexed. Exclusions specific to study drug were: history of venous thromboembolism or severe autoimmunity. The protocol was approved by the Institutional Human Research Ethics Committee and participants provided written informed consent. Australia New Zealand Clinical Trials Registry number ACTRN12609000294257.

**Treatment and outcome assessment**

Patients received cisplatin 75 mg/m2 and pemetrexed 500 mg/m2 on day 1 of a 21 day cycle to maximum 6 cycles with vitamin B12 and folate supplementation. CP-870,893 was given on day 8 each cycle, at three dose levels in consecutive patient cohorts: 0.1 mg/kg; 0.2 mg/kg; with 0.15 mg/kg as a de-escalation level. Patients received premedication for cytokine release reaction before CP-870,893 administration as previously described [9]. Prophylactic medications for chemotherapy included corticosteroids (days –1 to 2) and antiemetics; other anti-cancer treatments were not allowed. Chemotherapy was stopped before 6 cycles in the event of progression, unacceptable toxicity, or patient withdrawal; in this event, CP-870,893 was also stopped. Patients with stable or responding tumour at 6 cycles could continue single agent CP-870,893 every 21 days for a further 6 cycles at the same dose level, ceasing on progression or toxicity. Complete blood count, hepatic and renal function tests, and toxicity assessment were performed weekly on combination treatment and three-weekly on CP-870,893 alone. Clinical, imaging, and time to event outcome assessments have been described previously [9].

**Cell preparation**

**Peripheral blood volumetric cell counts**

Whole blood was analysed by flow cytometry on the day of collection to obtain absolute volumetric cell counts (cells per mL) of CD3+CD8+ and CD3+CD4+ T cells. Blood samples were stained using CD4-AlexaFluor488, CD3-PE and CD8-PECy7 antibodies as detailed in Table 1. Fixation and red blood cell lysis was performed using BD FACS lysing buffer, and data collected by three-color analysis using a Millipore Guava and Guava ExpressPro Software.

**PBMC Isolation**

Whole blood for PBMC isolation was collected into BD K2EDTA Vacutainers (BD Diagnostics, Australia) weekly during combined treatment (days 1, 8, 15), always prior to treatment administration (Fig. 1a). PBMC were isolated by Ficoll-Paque™ density gradient centrifugation, and cryopreserved in liquid nitrogen until analysis. Dual baseline samples were collected within 14 days of day 1, and pre-treatment on day 1 cycle 1. Serial analyses were performed on cryopreserved PBMCs, with all samples analysed concurrently for individual patients ensuring comparable experimental conditions across time points.

**PBMC flow cytometry**

PBMCs were thawed for 1 min at 37 °C and washed once in RPMI (Invitrogen), followed by two washes in PBS after putting cells into 96-well U-bottom plates (1 x 10⁶ cells / well). PBMC were stained for expression of surface markers using specific anti-human monoclonal antibodies (mAb) comprising three 8-colour panels as detailed in Table 1. Dead cells were identified using LIVE/DEAD Fixable Dead Cell Stain Kit (Thermo Fisher Scientific, Waltham, MA, USA).

DC were identified as staining with MHC Class II (HLA-DR-V500), and negative for a lineage cocktail of CD3-PerCP-Cy5.5, CD14-PerCP-Cy5.5, CD16-PerCP-Cy5.5, CD19-PerCP-Cy5.5, CD20-PerCP-Cy5.5, CD56-PerCP-Cy5.5 and LIVE/DEAD Fixable Red viability stain. Within this population, DC subsets were identified by antibodies against BDCA-1-PE, BDCA-2-FITC and BDCA-3-APC. Expression of CD40 was assessed within these subpopulations by CD40-APC-H7 staining.

CD4+ T cells were identified by positive staining for CD3-V450 and CD4-APC-H7, and negative for a lineage cocktail of CD19-V500, CD14-V500 and LIVE/DEAD.
Fixable Aqua viability stain. Tregs were identified within the CD3+ CD4+ T cell population by staining with CD25-APC, Foxp3-PE, and low CD127-PECy7. Within the Treg subset, cells were further assessed for staining by Ki67-FITC and ICOS-PerCP-Cy5.5. CD8+ T cells were identified by positive staining for CD3-V450 and CD8-APC-H7, and negative for a lineage cocktail of CD19-V500, CD14-V500 and LIVE/DEAD Fixable Aqua viability stain. Within the CD8+ population, activated effector cells were identified by HLA-DR-PECy7 and CD38-AlexaFluor647. These cells were also assessed for staining by Ki67-FITC, ICOS-PerCP-Cy5.5 and Bcl2-PE. Samples were run on a FACSCanto II flow cytometer using FACSDiva software (both BD Biosciences). At least 50,000 lymphocyte events were collected per sample. Data were analysed using FlowJo software (Tree Star Inc., Ashland, OR, USA).

**Statistical analysis**

Linear mixed models were used to analyse the relationship between time and lymphocyte subsets, in addition to testing for interaction. Analysis used the R environment for statistical computing and IBM SPSS for Windows statistical package version 23. Bar graphs showing treatment means were analysed using ANOVA, *P* values are multiplicity adjusted using Dunn multiple comparisons tests.

Exploratory analysis for correlation of DC or T cell subtypes with overall survival (OS) was performed separately for each sample collection time point between baseline and Cycle 3 Day 8. Patients were grouped above or below the median according to proportional presence of the DC or T cell subset under investigation. OS was analysed using the Kaplan Meier method, differences in OS between groups were calculated using the Mantel-Cox Log Rank test. No corrections for multiple comparisons were performed here as analyses were exploratory and hypothesis-generating.
Fig. 1 (See legend on next page.)
Results
Sixteen patients with radiologically assessable malignant mesothelioma were enrolled as described previously [9]. Patients were treated and PBMC samples collected as described in the materials and methods section and Fig. 1a. We analysed all patient PBMC samples by flow cytometry and here report on DC, and CD4 or CD8 T cell subsets. Linear mixed modelling of the data allowed us to not only assess immunological changes from week to week in response to different components of the treatment regimen, but also to examine longitudinal changes across 6 cycles of treatment.

Dendritic cell subpopulations
Blood DC subpopulations were identified by flow cytometry on the basis of BDCA marker expression using the gating strategy as shown in Fig. 1b (see discussion for DC subpopulation characteristics and roles). Whilst our data on the proportion of these DC subpopulations as a fraction of total PBMC showed a wide variability, both within and between individual patients over 6 cycles of chemoimmunotherapy treatment, the pattern of change was cyclical and consistent for BDCA-1+ and BDCA-2+ (CD303+ plasmacytoid) DC (Fig. 1c). In both these DC subsets, a marked proportional decrease of around 50% was observed prior to Day 1 of each cycle, coinciding with pre-chemotherapy medication with the glucocorticoid steroid dexamethasone [14]. The proportion of BDCA-2+ DC remained low until Day 15 of each cycle before returning to baseline levels, whereas a recovery in BDCA-1+ DCs was seen a week earlier at Day 8 (Fig. 1c). The less numerous, BDCA-3+ (CD141+ myeloid), DC showed a more complex profile, with linear mixed modelling indicating a rebound significantly above baseline levels by Day 1 of each treatment cycle. The ratio of BDCA-1+ to BDCA-2+ DC was variable, reflecting the differential recovery of BDCA-1+ and BDCA-2+ subsets on Day 8 and Day 15 respectively, with these differences becoming less pronounced as the number of treatment cycles progressed (Fig. 1d).

Dendritic cell functional markers
Relative expression levels of both CD40 and HLA-DR were assessed by mean fluorescence intensity (MFI) of staining (Fig. 2). CD40 was expressed at highest levels on BDCA-1+ DC, and lowest levels on BDCA-3+ DC. Linear mixed modelling revealed a cyclical pattern of CD40 expression on all three subsets. BDCA-1+ DC expressed most CD40 at Day 1 of each cycle (after dexamethasone premedication), returning to baseline (pre-corticosteroid) levels at Day 8 and Day 15. CD40 expression on BDCA-2+ DC was seen to decrease slightly from baseline levels at Day 1, with a more substantial decrease by Day 8 before returning to baseline levels by Day 15 of each cycle. BDCA-3+ DC displayed upregulation of CD40 at Day 1 and Day 8, decreasing back to baseline levels at Day 15. However, none of the DC subsets investigated here exhibited a significant overall change in the levels of CD40 expression across 6 cycles of combined chemoimmunotherapy.

HLA-DR expression was highly variable. Linear mixed modelling indicated that HLA-DR expression levels were also modulated in a cyclical fashion to some degree, and on BDCA-1+ DC showed a statistically significant, but minor, decrease between the start and end of treatment. Cyclical changes in HLA-DR expression on BDCA-2+ DC were minimal, and general HLA-DR levels as measured by MFI were lower than the other DC subsets. HLA-DR expression on BDCA-1+ DC showed a marked decrease at Day 1 of each cycle before rebounding, whereas BDCA-3+ DC displayed an increase in HLA-DR levels at Day 8 followed by a sustained decrease by Day 15 of each cycle.

Flow cytometry data on DC subset representation and relative expression of functional markers underwent exploratory analyses for correlation with overall survival (OS), separately for each time point between baseline and Cycle 3 Day 8. For a full list of parameters analysed,
see Table 2. The majority of analyses showed no significant differences in OS above vs below the median, however those patients who had higher than the median proportion of BDCA-2+ DC at baseline have longer OS (Fig. 3a), and patients who have higher than the median proportion of BDCA-3+ DC when CP-870,893 was delivered (Day 8) during Cycle 2 and Cycle 3 had poorer OS (Fig. 3b).

Stability of T cell number and subset distribution

T cell concentrations per microlitre of peripheral blood were recorded for each sample prior to PBMC isolation (Fig. 4a). Variation in overall number of CD3+ T cells, as well as the proportion of CD4+ and CD8+ cells fluctuated in a repetitive manner each treatment cycle, with the number of T cells halving at Day 1, and returning to baseline levels at Day 8 and Day 15 (Fig. 4b). Treatment did not affect CD4+ and CD8+ numbers in an identical manner, with the CD8+ to CD4+ ratio becoming skewed in favour of CD8+ T cells at Day 1 of each cycle after dexamethasone and immediately prior to chemotherapy, and returning to around baseline levels by Day 8 and Day 15 of each cycle, a pattern consistent with a treatment dependent CD4 depletion. With each additional cycle of chemoimmunotherapy the scale of CD4+ T cell depletion became more pronounced, but remained transient such that the balance between CD4 and CD8 always returned to baseline by Day 15 of each cycle (Fig. 4c).

CD8+ T cell proliferating, activated and effector populations

We further analysed the CD8+ T cell compartment for markers of proliferation and activation (see Fig. 5a for flow cytometry gating strategy). Proliferation was assessed by intracellular staining for Ki67, expressed in dividing and recently-divided cells [15]. Proliferation was seen to be highly cyclical, with the lowest proportion of Ki67+ cells consistently observed one week after chemotherapy (at Day 8) and the highest degree of proliferation one week after immunotherapy (at Day 15) for each cycle (Fig. 5b). The inducible co-stimulator molecule (ICOS), a member of the CD28 co-stimulator family, is expressed on activated T cells and is associated with antigen recognition [16, 17]. ICOS expression exhibited a similar pattern to Ki67, with a sharp decrease
coinciding with blood samples collected one week following chemotherapy (Day 8) before returning to baseline levels (Fig. 5b). We also examined "effector" CD38\(^{\text{hi}}\)HLA-DR\(^{\text{hi}}\) CD8\(^{+}\) T cells, which are activated in an antigen-specific manner as previously reported from studies of chronic viral infection, and are present at elevated levels in cancers including mesothelioma compared with healthy controls [18–22]. These cells are predominantly proliferating, and exhibit low expression of Bcl-2 (an anti-apoptotic protein downregulated following antigen-specific T cell activation) [19, 23].

Our raw data and subsequent linear mixed modelling data again show a marked cyclical pattern over each cycle of chemoimmunotherapy treatment, with the effector proportion of CD8\(^{+}\) T cells peaking at Day 1 of each cycle after dexamethasone prior to falling just below baseline levels at Day 8 following chemotherapy (Fig. 5b). None of the CD8\(^{+}\) T cell parameters described above showed a significant change over the 6 cycles of chemoimmunotherapy.

**CD4\(^{+}\) T cell proliferating, activated and regulatory populations**

CD4\(^{+}\) T cells were also assessed by flow cytometry for overall proliferation (Ki67), activation (ICOS), and for the proportion of CD25\(^{+}\)CD127\(^{lo}\)Foxp3\(^{+}\) regulatory T cells (Tregs) present within the CD4\(^{+}\) T cell compartment, using the gating strategy described in Fig. 6a. Overall, CD4\(^{+}\) T cells exhibited a broadly similar profile for fluctuations in proliferation and activation as CD8\(^{+}\) T cells, with significant reductions in the proportion of both Ki67\(^{+}\) and ICOS\(^{+}\) cells at Day 8 of each cycle, one week following chemotherapy (Fig. 6b). Analysis of Tregs also revealed a cyclical pattern, albeit less pronounced, with Tregs decreasing by approximately 20% between Day 1 and Day 8 of each treatment cycle followed by a return to around baseline levels a week later (Fig. 6b). There was no change over the six treatment cycles in any CD4\(^{+}\) T cell populations.

Flow cytometry data on T cell subset representation and expression of activational markers underwent exploratory analysis for correlation with OS, separately for each time point between baseline and Cycle 3 Day 8.

---

**Table 2 Data analysed for correlation with overall survival**

| DC parameters | T cell parameters |
|---------------|------------------|
| DC (HLA-DR+ lin-) % of PBMC | CD8 + % of CD3+ |
| BDCA-1+ DC % of total PBMC | K67+% of CD8 T cells |
| BDCA-2+ DC % of total PBMC | ICOS+% of CD8 T cells |
| BDCA-3+ DC % of total PBMC | Taff (HLA-DR+CD38+) % of CD8 T cells |
| BDCA-1+ % of DC | CD3% of lymphocytes |
| BDCA-2+ % of DC | CD4% of CD3+ |
| BDCA-3+ % of DC | K67% of CD4 T cells |
| BDCA-1+BDCA-2+ ratio | ICOS% of CD4 T cells |
| BDCA-1+BDCA-3+ ratio | Treg% of CD4 T cells |
| BDCA-2+BDCA-3+ ratio | ki67% of Treg (CD25\(^{+}\)CD127\(^{lo}\)Foxp3\(^{+}\)) |
| BDCA-1+ DC HLA-DR MFI | ICOS + % of Treg (CD25\(^{+}\)CD127\(^{lo}\)Foxp3\(^{+}\)) |
| BDCA-2+ DC HLA-DR MFI | |
| BDCA-3+ DC HLA-DR MFI | |
| BDCA-3+ DC HLA-DR MFI | |

List of parameters undergoing exploratory analysis for correlation with OS. Flow cytometry data was used to group patients above or below the median for each parameter, and repeated using data from each sample collection time point from baseline through to Cycle 3 Day 8.

---

**Fig. 3** Overall survival analysed by grouping patients above and below the median for (a) BDCA-2+ DC % of total PBMC at baseline, and (b) BDCA-3+ DC % of total PBMC at cycle 2 day 8 or cycle 3 day 8. Statistical significance calculated using Mantel Cox log rank test. Solid and dotted lines show data above and below the median values, respectively.
Table 2. The majority of analyses showed no significant differences in OS above vs below the median, however those patients who had an ICOS+ % of CD8+ T cells above the median at baseline achieved better OS (Fig. 7). Both positive predictors of better OS in baseline samples, BDCA2+ DC% and ICOS+ % of CD8+ T cells, were seen to correlate ($r = 0.563$, $p = 0.029$).

**Discussion**

It is becoming increasingly important to identify immune biomarkers in patients treated with the variety of...
immunotherapies currently being developed; both to assist with clinical decision making and to help understand the immunological basis of response, or lack thereof. Given that activating anti-CD40 has strong preclinical and early clinical evidence of efficacy, we undertook this study of systemic immune parameters to establish the pattern of changes induced by this agent in the context of chemotherapy, and to undertake an exploratory analysis of any correlation between these changes and patient outcomes.

We recently published the results from a phase Ib clinical trial combining the anti-CD40 agonist antibody CP-870,893 with cisplatin/pemetrexed chemotherapy in patients with mesothelioma [9]. We
demonstrated the combination was well tolerated, and had at least equivalent efficacy to chemotherapy alone. In an earlier study, Vonderheide et al. documented short-term changes in various immunological parameters immediately following CP-870,893 infusion on B cells in particular, and in our original report we described similar changes in B cell markers over 6 treatment cycles [4]. Here, we expand this longitudinal analysis of immune parameters to include data on dendritic cells and T cells, and show how, in the context of chemotherapy, CP-870,893 induces alterations in these cell populations.

Changes in B cells are one of the clearest immunopharmacodynamic indicators of CP-870,893 activity both...
in this and the previous study. This is not unexpected
since B cells are the largest leukocyte subset that express
the target of the drug, CD40. Notwithstanding this, the
proposed mechanism of action of the drug is via agonistic
activation of DC through the CD40 receptor [24, 25].
However, it remains to be clarified which DC subsets may
be involved in anti-CD40 mediated tumour immunity.

BDCA-1+ (CD1c+) DC are the most numerous mye-
loid DC population, maturing into both tissue and
lymph node DC that are potent activators of CD4+ T
cells. BDCA-2+ (CD303+) plasmacytoid DC are present
in the blood at similar concentrations to BDCA-1+ DC
and are primarily lymphoid DC precursors; these play a
key role in responding to viral infection through type 1
interferon release. BDCA-3+ (CD141+) myeloid DC are
a smaller population, typically making up around 10% of
total blood DC, and have a major role in cross-
presentation of antigen to CD8+ T cells. See refs [26, 27],
and for recent reviews on DC subtypes and nomenclature
[26, 27]. We report that the proportion of the two major
DC subsets, BDCA-1+ (CD1c+ myeloid) and BDCA-2+
(CD303+ plasmacytoid), decreased sharply as a proportion
of total PMBC in response to dexamethasone treatment
as previously described, but it was not apparent that anti-
CD40 treatment itself (i.e. between Day 8 and Day 15)
induced any changes away from baseline in either propor-
tional presence of any DC subsets at the time points
chosen for this study [14]. A previous study by Ruter et al.
reported that depletion from peripheral blood of CD11c +
CD123dim CD14– DC was observed in the shorter term,
although data were not shown [10].

It may be that direct binding to the CD40 molecule by
CP-870,893 can modulate CD40 expression, but this was not observed - either because no such modulation oc-
curred, or alternatively because it was simply not de-
tected due to post-CP-870,893 blood collection being
scheduled one week following drug administration, with
any modulations occurring in the shorter term. Indeed,
this was the case with data on B cell populations in pre-
vious work from this study [9]. Although expression of
the MHC-class II molecule HLA-DR had a downward
trend over 6 cycles of chemoimmunotherapy in all three
DC subsets examined, this was only statistically signifi-
cant in BDCA-1+ DC (p = 0.022) and we do not con-
sider the magnitude of this decrease to be biologically
relevant. A 2007 study by Hunter and colleagues re-
ported that HLA-DR expression increased in response
to CP-870,893 treatment of monocyte-derived DC in
vitro over a 24 h time window. Similarly, whilst pro-
duced immediate and short term effects of CP-870,893
on B cells were identified, these parameters returned to
baseline by day 8 after treatment [4]. Therefore it is pos-
sible that any increase was transient and not detected by
us 7 days after treatment [11].

Weekly CP-870,893 monotherapy has been shown to
reduce lymphocyte concentrations in peripheral blood to
below 50% of baseline counts two days after treatment
at MTD, followed by rebound to pretreatment levels, al-
though this has not been observed for less frequent dos-
ing schedules [4]. Across the longer term, however, our
combination of cisplatin/pemetrexed and anti-CD40
gives similar outcomes to anti-CD40 monotherapy, with
some variation between patients but generally no overall
change in lymphocyte concentration observed [7, 10].
Ruter and colleagues also noted a bias toward depletion
of CD4+ over CD8+ T cells and indeed our linear mixed
modelling shows that over 6 cycles of chemotherapy this
may be the case – particularly at Day 1 of each cycle,
directly prior to administration of chemotherapy [10].
However our observation is also small in scale, and we
are unable to say definitively whether anti-CD40 may be
responsible. A high intrapatient variability in the propor-
tional presence of Tregs was observed, but was generally
modulated consistently within individual patients in re-
response to treatment, no long term changes appeared to
be uniformly induced with this 6-cycle treatment sched-
ule in agreement with past studies [7, 10].

Our exploratory analyses of the relationship between
immunological parameters and patient outcomes
highlighted a potential relationship between either
higher-than-median BDCA-2 + DC% of PBMC at base-
line, or lower-than-median BDCA-3 + % at C2D8 and
C3D8, and longer patient survival. Mechanistically, it is possible that a higher proportion of BDCA-2+ DC at baseline indicates a larger number of target cells available for the action of anti-CD40 therapy, potentially giving a useful prognostic indicator for those patients likely to achieve better responses. The seemingly beneficial link between a reduction in antigen cross-presenting BDCA-3+ DC and better OS, however, might seem contrary to expectation if an anti-tumour immune response is thought to be underlying the difference in survival. However, it may be that these BDCA-3+ are migrating out of the peripheral blood and into other tissues, potentially as a result of anti-CD40 inducing the maturation of these cells, and may therefore be indicative of those patients achieving better responses. Exploratory analyses in the T cell compartment revealed a correlation between OS and the ICOS + % of CD8+ T cells at baseline. The postulated mechanism of CP-870,893 action is to increase APC-mediated CD8+ T cell activation and it may be that those patients with higher-than-median CD8 activation prior to treatment have an immune landscape that is already predisposed toward this outcome; thus, addition of anti-CD40 is sufficient to tip the balance further in favour of a better anti-tumour response in those individuals. It is interesting to note that both parameters showing differences in OS at baseline, BDCA2+ DC and ICOS+ CD8 T cells, correlated in this sample set and may be worth further investigation. We acknowledge these data were obtained from a small number of patients and serve only as hypothesis-generating, however they may inform investigators in future clinical trials that include greater numbers of participants.

The interpretation of our results is complicated because each of the three administered agents have potential immune-modulating effects, and each was given at different stages of the 21-day treatment cycle. Nevertheless, this complexity is an emerging reality in human cancer immunotherapy, where single agents have promising but insufficient activity and where combinations are now under intense investigation. Firstly, characteristics of samples taken at Day 1 of each cycle (taken immediately before infusion of pemetrexed/cisplatin) were influenced by three doses of the glucocorticoid steroid dexamethasone, with a cumulative dose of 12 mg given in the 24 h leading up to chemotherapy. Dexamethasone is given prior to and for three to five days after pemetrexed/cisplatin for control of skin rash, emesis and inflammatory side effects, and has been shown to cause alterations in the majority of immune parameters examined in this paper; for example lymphodepletion and alteration of DC subsets [14]. Secondly, the effects of chemotherapy itself, given on Day 1 of each treatment cycle here and evident one week later at Day 8. The effects of cisplatin/pemetrexed are well known, particularly with respect to depletion of proliferating and activated cells as can be observed from our lymphocyte data, and may well alter the immunological background of patients in a manner that can affect the subsequent dose of anti-CD40. We have previously demonstrated a profound reduction in the proportion of Ki67+ CD8+, CD4+ and Treg as well as activated effector CD8+ T cells on day 8 after chemotherapy, which recovers to baseline prior to the next chemotherapy cycle [18]. Thirdly, the effects of the agonistic anti-CD40 antibody, administered on Day 8. As described above, pharmacodynamics of CP-870,893 with respect to parameters of the adaptive immune system are generally observed over a shorter time window (3–4 days) [4, 10]. It is therefore probable that the majority of direct effects of anti-CD40 have reset by the time the next blood sample is collected at Day 15, hence were not observed as part of the inter-cycle variation in our study.

An important message from this study is that investigators must undertake careful preliminary pharmacodynamic immunological studies when selecting time points for immunological biomarker investigation in patients who are undergoing concurrent chemoimmuno-therapy. Although longitudinal samples from patients provide the opportunity to identify predictive biomarkers for response to combination therapy, it is more complicated to attribute changes in defined immunological parameters to individual drugs within this combination without the inclusion of control arms to the study. Ideally, control arms would monitor immunological parameters in individual agents, however this is not always practical or feasible with small signal-finding studies and phase Ib studies. Consistency in timing of immunological sampling is paramount, with the potential for alteration in immunological parameters by supportive care medications and chemotherapy in addition to immunotherapies. A pre-corticosteroid baseline is also essential; some chemotherapy regimens have an absolute requirement for corticosteroid premedication which cannot be modified. Furthermore, in many clinical trials there is an allowable window for blood sampling which may include +/- one to two days which may risk adding to the complexity of result interpretation. Statistical techniques such as the linear mixed modelling used in this study can enhance the clarity of interpretation of complex, cyclical data and facilitate an understanding of change over time. However, only the availability of a control group receiving chemotherapy and supportive care alone will allow the contributions
of immunotherapy to biomarker changes to be definitively evaluated.

Conclusions
This study did not find any longitudinal changes in the profile of dendritic cells or T cells associated with this treatment, and conclude that B cells remain the best indicator of CP-870,893 pharmacodynamic activity across multiple cycles of treatment in combination with pemetrexed and cisplatin. Careful consideration of scheduling, consistency, and premedications is required in interpreted immunological change in chemotherapy trials. The availability of a control group is likely critical to robust interpretation of any potential biomarkers.

Abbreviations
APC: Antigen presenting cell; DC: Dendritic cell; ICOS: Inducible co-stimulator; MTD: Maximum tolerated dose; OS: Overall survival; PBMC: Peripheral blood mononuclear cell; Treg: Regulatory T cell

Acknowledgements
The authors acknowledge the facilities, and the scientific and technical assistance of the Australian Microscopy & Microanalysis Research Facility at the Centre for Microscopy, Characterisation & Analysis, the University of Western Australia, a facility funded by the University, State and Commonwealth Governments.

Funding
Funding was obtained from Pfizer Inc. to cover costs of clinical trial administration. Laboratory work, data analysis and consumables were funded by the Insurance Commission of Western Australia, the Cancer Council of Western Australia, and the Australian National Health and Medical Research Council. None of these funding bodies had a role in study design, nor collection, analysis and interpretation of the data or in writing the manuscript.

Availability of data and materials
The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
AMM and AMC collected and analysed flow cytometry data. AMC prepared the manuscript. AKN recruited and managed study participants. All authors contributed to study conception, study funding, study conduct, and experimental design. All authors read, edited and approved the final manuscript.

Competing interests
CP-870,893 antibody was supplied by Pfizer Inc, who had no role in study design, sample collection, data analysis, data interpretation or writing of the manuscript.

Consent for publication
Not applicable

Ethics approval and consent to participate
The study was approved by the Sir Charles Gairdner Hospital Human Research Ethics Committee (2008-148) and all participants provided written informed consent.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1School of Medicine and Pharmacology, The University of Western Australia, Crawley, WA 6009, Australia. 2National Centre for Asbestos Related Diseases, The University of Western Australia, Crawley, WA 6009, Australia. 3Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia. 4Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia.

Received: 13 October 2016 Accepted: 6 June 2017
Published online: 15 June 2017

References
1. Eliopoulos AG, Young LS. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr Opin Pharmacol. 2004;4(4):360–7.
2. Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res. 2013;19(5):1035–43.
3. Khong A, Nelson DJ, Nowak AK, Lake RA, Robinson BW. The use of agonistic anti-CD40 therapy in treatments for cancer. Int Rev Immunol. 2012;31(4):246–66.
4. Vonderheide RH, Flaherty KT, Khaili M, Stumacher MS, Bajor DL, Hutnick NA, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007;25(7):876–83.
5. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 2010;63(15):4990–6.
6. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331(6024):1612–6.
7. Vonderheide RH, Burg JM, Mick R, Troso JA, Li D, Shaik MN, et al. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology. 2013;2(1):e28033.
8. Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res. 2013;19(22):6286–95.
9. Nowak AK, Cook AM, McDonnell A, Millward M, Creaney J, Francis RJ, Hasani A, Segal A, Musk AW, Turlach BA et al: A phase 1b clinical trial of the CD40 activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Ann Oncol 2015 (in press).
10. Ruter J, Antonia SJ, Burris HA, Huhn RD, Vonderheide RH. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol Ther. 2010;10(10):983–93.
11. Hunter TB, Alsaari M, Gladue RP, Bedian V, Antonia SJ. An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model. Scand J Immunol. 2007;65(S1):79–86.
12. Byrne MJ. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2004;15(2):257–60.
13. Francis RJ, Byrne MJ, van der Schaar AA, Boucek JA, Phillips M, Price R, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med. 2007;48(9):1449–58.
14. Cook AM, McDonnell AM, Lake RA, Nowak AK. Desmethylfasorotenone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies. Oncoimmunology. 2016;5(3):e1066062.
15. Gerdes J, Lemke H, Baisch J, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol (Baltimore, Md : 1950). 1984;133(4):1710–5.
16. Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol. 2003;3(12):939–51.
17. Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature. 1999;397(6716):263–6.
18. McCoy MJ, Nowak AK, van der Most RG, Dick IM, Lake RA. Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies. Cancer immunol immunother. 2012;62(3):529–39.

19. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity. 2008;28(5):710–22.

20. Appay V, Dunbar PR, Callan M, Klennerman P, Gillespie GMA, Papagno L, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8(4):379–85.

21. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med. 2000;191(9):1499–512.

22. Callan MF, Tan L, Annels N, Ogg GS, Wilson JD, O’Callaghan CA, et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med. 1998;187(9):1395–402.

23. Hildeman DA, Zhu Y, Mitchell TC, Boullet P, Strasser A, Kappeler J, et al. Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim. Immunity. 2002;16(6):759–67.

24. Carpenter EL, Mick R, Ruter J, Vonderheide RH. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. J Transl Med. 2009;7:93.

25. Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res. 2007;13(4):1083–8.

26. Boltjes A, Van Wijk F. Human dendritic cell functional specialization in steady-state and inflammation. Front Immunol. 2014;5:131.

27. Collin M, McGovern N, Haniffa M. Human dendritic cell subsets. Immunology. 2013;140(1):22-30.